Tradestie Institutional Equity Comparison Engine
SRZN vs KTTA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRZN Overall Edge
SRZN Captures Institutional Edge (2โ1 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Momentum & Technical, Options & Structure while KTTA counters with relative strength in Growth & Margin. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus KTTA at N/M Forward P/E and 0.0% operating margin (+1498.1% YoY). In options structure, SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against KTTA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SRZN N/M vs KTTA N/M Fwd P/E
Growth & Margin Winner
KTTA
Op Margin -485.4% vs 0.0% ยท YoY +408.6% vs +1498.1%
Momentum & Technical Winner
SRZN
1Y +110.8% vs +0.6% ยท 52W Pos 63% vs 11%
Options & Structure Winner
SRZN
CONSOLIDATION (13th %ile IV) vs UNCLASSIFIED (N/A IV)
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap
$642.7M
1M Return
+10.52%
1Y Return
+110.81%
Forward P/E
N/M
Unified AI Score
36.0 / 100
SELL
Tech 15.0
Fund 42.0
Flow 65.0
Mom 50.0
KTTA
NASDAQ
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap
$17.7M
1M Return
+7.52%
1Y Return
+0.59%
Forward P/E
N/M
Unified AI Score
42.1 / 100
HOLD
Tech 20.0
Fund 40.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SRZN +110.81%
KTTA +0.59%
Spread: +110.22 pp (SRZN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRZN Revenue | KTTA Revenue | SRZN Op. Margin | KTTA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2021 | N/A | $0M | N/A | -29925.7% | KTTA |
| FY2022 | $10M | $0M | -354.7% | -2587.3% | SRZN |
| FY2024 | $10M | N/A | -239.7% | N/A | SRZN |
| FY2025 | $0M | N/A | -1210.6% | N/A | SRZN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SRZN | KTTA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $642.7M | $17.7M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +408.6% | +1498.1% | Higher Growth | KTTA |
| Operating Margin (TTM) Profitability | -485.4% | 0.0% | Higher Margin | KTTA |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -62.8% | -88.8% | Higher ROE | SRZN |
| 52-Week Range Position Momentum | 63% ($13โ$38) | 11% ($0โ$2) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 1.29ฮฒ ยท 73% Vol | 0.68ฮฒ ยท 185% Vol | Lower Realized Risk | SRZN |
| Unified Institutional Score Composite Signal | 36.0 / 100 (SELL) | 42.1 / 100 (HOLD) | Higher Composite | KTTA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SRZN vs KTTA Buy Guide
SRZN
CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
13th %ile
IV Regime
Compressed (<25th %ile)
KTTA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SRZN nor KTTA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.